Physician profile
Robert A Jason
NPI 1700260015
$3,978.97
in general payments reported to CMS, 2019-2025
34 companies · $779 in 2025
The $779 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $864 · 2021: $1,518 · 2022: $83.13 · 2023: $214 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $710.94 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Allergan, INC. | $334.67 | 2019-2020 | |
| Lilly USA, LLC | $308.90 | 2019-2021 | |
| Glaxosmithkline, LLC. | $282.62 | 2020-2025 | Shingrix |
| Janssen Pharmaceuticals, INC | $279.61 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.60 | 2020-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $191.19 | 2023 | Gemtesa |
| Pfizer INC. | $169.97 | 2020-2025 | |
| Amarin Pharma, INC. | $154.55 | 2020-2021 | |
| Alkermes, INC. | $146.23 | 2019-2022 | |
| Abbvie INC. | $136.59 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.18 | 2019-2021 | |
| Axsome Therapeutics, INC. | $96.85 | 2025 | Auvelity, Symbravo |
| Merck Sharp & Dohme LLC | $81.41 | 2020-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Xeris Pharmaceuticals, INC. | $80.60 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $79.70 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $70.28 | 2025 | Rexulti |
| Mylan Specialty L.P. | $66.05 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $63.49 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $54.52 | 2025 | |
| Indivior INC. | $52.83 | 2019 | |
| Viatris Specialty LLC | $46.48 | 2025 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.73 | 2025 | Caplyta |
| Exact Sciences Corporation | $35.02 | 2025 | The Cologuard Plus Collection Kit |
| Amgen INC. | $26.15 | 2019-2025 | Repatha, Otezla |
| Ferring Pharmaceuticals INC. | $20.28 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.20 | 2025 | Eliquis |
| Ironshore Pharmaceuticals INC. | $17.76 | 2021 | |
| Eisai INC. | $17.07 | 2025 | |
| Verity Pharmaceuticals INC. | $16.79 | 2025 | Tlando |
| Phadia US INC. | $14.28 | 2025 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $14.08 | 2025 | Zoryve |
| Vertex Pharmaceuticals Incorporated | $13.97 | 2025 | |
| Supernus Pharmaceuticals, INC. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.